Medicus Pharma (MDCX) Cash & Equivalents (2023 - 2025)

Medicus Pharma (MDCX) has reported Cash & Equivalents for 3 consecutive years, with $8.7 million the latest figure, recorded in Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $8.7 million, up 109.04% year-over-year; the trailing twelve-month figure through Dec 2025 was $8.7 million (up 109.04% YoY), and the FY2025 annual result was $8.7 million, up 109.04% from the prior year.
• Cash & Equivalents was $8.7 million for Q4 2025 at Medicus Pharma, roughly flat from $8.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $9.7 million in Q2 2025 and troughed at $1.7 million in Q4 2023.
• Average Cash & Equivalents over 3 years is $6.2 million, with a median of $6.4 million recorded in 2024.
• Year-over-year, Cash & Equivalents soared 142.21% in 2024 and surged 109.04% in 2025.
• Over 3 years, Cash & Equivalents stood at $1.7 million in 2023, then surged by 142.21% to $4.2 million in 2024, then soared by 109.04% to $8.7 million in 2025.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $8.7 million in Q4 2025, $8.7 million in Q3 2025, and $9.7 million in Q2 2025.